NO2513053T3 - - Google Patents
Info
- Publication number
- NO2513053T3 NO2513053T3 NO10792934A NO10792934A NO2513053T3 NO 2513053 T3 NO2513053 T3 NO 2513053T3 NO 10792934 A NO10792934 A NO 10792934A NO 10792934 A NO10792934 A NO 10792934A NO 2513053 T3 NO2513053 T3 NO 2513053T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306270 | 2009-12-18 | ||
| US37337010P | 2010-08-13 | 2010-08-13 | |
| US37601310P | 2010-08-23 | 2010-08-23 | |
| EP10792934.1A EP2513053B1 (en) | 2009-12-18 | 2010-12-17 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders |
| PCT/EP2010/070040 WO2011073376A1 (en) | 2009-12-18 | 2010-12-17 | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2513053T3 true NO2513053T3 (es) | 2018-03-03 |
Family
ID=42236460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO10792934A NO2513053T3 (es) | 2009-12-18 | 2010-12-17 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9695120B2 (es) |
| EP (2) | EP2513053B1 (es) |
| JP (1) | JP6144913B2 (es) |
| KR (1) | KR101827529B1 (es) |
| CN (1) | CN102812003B (es) |
| AU (1) | AU2010332765C1 (es) |
| BR (1) | BR112012018374B1 (es) |
| CA (1) | CA2784528C (es) |
| CY (1) | CY1119730T1 (es) |
| DK (1) | DK2513053T3 (es) |
| EA (1) | EA023861B3 (es) |
| ES (1) | ES2655091T3 (es) |
| HR (1) | HRP20171991T1 (es) |
| HU (1) | HUE038064T2 (es) |
| LT (1) | LT2513053T (es) |
| MX (1) | MX339252B (es) |
| NO (1) | NO2513053T3 (es) |
| PL (1) | PL2513053T3 (es) |
| PT (1) | PT2513053T (es) |
| RS (1) | RS56751B1 (es) |
| SI (1) | SI2513053T1 (es) |
| WO (1) | WO2011073376A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2784528C (en) * | 2009-12-18 | 2018-05-01 | Euroscreen Sa | Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43) |
| WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| NZ626973A (en) | 2012-01-06 | 2016-09-30 | Novartis Ag | Heterocyclic compounds and methods for their use |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| CA2929436C (en) * | 2013-11-27 | 2021-06-15 | Euroscreen Sa | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| KR101656662B1 (ko) | 2014-11-18 | 2016-09-12 | 한국생명공학연구원 | 2-옥소-1,2,3,4-테트라하이드로피리미딘-5-카르복사미드 유도체를 유효성분으로 함유하는 대사성 질환 예방 또는 치료용 약학적 조성물 |
| CN107033015B (zh) * | 2017-06-02 | 2019-04-30 | 南京欧信医药技术有限公司 | 一种药物中间体的合成方法 |
| SG11202007646UA (en) | 2018-02-13 | 2020-09-29 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020205867A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| WO2021018786A1 (en) | 2019-07-26 | 2021-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection |
| CN110981779B (zh) * | 2019-11-23 | 2021-02-26 | 武汉理工大学 | R-2-(2,5-二氟苯基)吡咯烷的合成方法 |
| BR112022025065A2 (pt) | 2020-06-10 | 2022-12-27 | Epics Therapeutics | Síntese de ácido (2s,5r)-5-(2-clorofenil)-1-(2'-metoxi-[1,1'-bifenil]-4- carbonil)pirrolidina-2-carboxílico |
| US20240132447A1 (en) | 2022-10-11 | 2024-04-25 | Epics Therapeutics | Polymorphs of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542788A (en) | 1968-06-12 | 1970-11-24 | Searle & Co | 1-amino-5-phenyl-2-pyrrolepropionic acid and congeners |
| US4006075A (en) | 1975-01-06 | 1977-02-01 | Exxon Research And Engineering Company | Method of regenerating a cracking catalyst with substantially complete combustion of carbon monoxide |
| DE3421295A1 (de) | 1984-06-08 | 1985-12-12 | Basf Ag, 6700 Ludwigshafen | Neue pyrrolidincarbonsaeurederivative, verfahren zu ihrer herstellung |
| JPH06104658B2 (ja) * | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | ピロールカルボン酸誘導体 |
| FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
| GB9206757D0 (en) * | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| JP3005469B2 (ja) | 1996-06-05 | 2000-01-31 | 住友軽金属工業株式会社 | 内面スズめっき長尺銅管の製造方法 |
| US6177464B1 (en) | 1997-03-14 | 2001-01-23 | Sepracor, Inc. | Ring opening metathesis of alkenes |
| US6713502B2 (en) | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| WO2003037895A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| FI20030014A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| US20040142379A1 (en) * | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| JP2007501844A (ja) * | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| TW200528107A (en) * | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| US7576175B2 (en) * | 2004-05-27 | 2009-08-18 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| US9017949B2 (en) | 2004-09-22 | 2015-04-28 | Arena Pharmacueticals, Inc. | Method of screening for compounds useful in the treatment of insulin resistance, impaired glucose tolerance or diabetes |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| WO2009003009A1 (en) * | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolidine as anti-infectives |
| US20090233972A1 (en) | 2008-03-12 | 2009-09-17 | Yat Sun Or | Substituted heterocycles as anti-infectives |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| CA2784528C (en) * | 2009-12-18 | 2018-05-01 | Euroscreen Sa | Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43) |
-
2010
- 2010-12-17 CA CA2784528A patent/CA2784528C/en active Active
- 2010-12-17 ES ES10792934T patent/ES2655091T3/es active Active
- 2010-12-17 NO NO10792934A patent/NO2513053T3/no unknown
- 2010-12-17 AU AU2010332765A patent/AU2010332765C1/en active Active
- 2010-12-17 CN CN201080064345.3A patent/CN102812003B/zh active Active
- 2010-12-17 EP EP10792934.1A patent/EP2513053B1/en active Active
- 2010-12-17 DK DK10792934.1T patent/DK2513053T3/en active
- 2010-12-17 RS RS20171317A patent/RS56751B1/sr unknown
- 2010-12-17 PT PT107929341T patent/PT2513053T/pt unknown
- 2010-12-17 WO PCT/EP2010/070040 patent/WO2011073376A1/en active Application Filing
- 2010-12-17 JP JP2012543780A patent/JP6144913B2/ja active Active
- 2010-12-17 BR BR112012018374-5A patent/BR112012018374B1/pt active IP Right Grant
- 2010-12-17 SI SI201031607T patent/SI2513053T1/en unknown
- 2010-12-17 MX MX2012007030A patent/MX339252B/es active IP Right Grant
- 2010-12-17 KR KR1020127018966A patent/KR101827529B1/ko active IP Right Grant
- 2010-12-17 EA EA201200918A patent/EA023861B3/ru active IP Right Maintenance
- 2010-12-17 PL PL10792934T patent/PL2513053T3/pl unknown
- 2010-12-17 LT LTEP10792934.1T patent/LT2513053T/lt unknown
- 2010-12-17 HU HUE10792934A patent/HUE038064T2/hu unknown
- 2010-12-17 EP EP17175370.0A patent/EP3255038A1/en not_active Withdrawn
-
2012
- 2012-06-18 US US13/526,337 patent/US9695120B2/en active Active
-
2017
- 2017-06-15 US US15/624,290 patent/US10017468B2/en active Active
- 2017-12-21 HR HRP20171991TT patent/HRP20171991T1/hr unknown
-
2018
- 2018-01-04 CY CY20181100010T patent/CY1119730T1/el unknown
- 2018-06-20 US US16/013,281 patent/US10358416B2/en active Active
-
2019
- 2019-06-18 US US16/444,781 patent/US10577318B2/en active Active
-
2020
- 2020-01-17 US US16/745,727 patent/US10781171B2/en active Active
- 2020-07-15 US US16/929,573 patent/US11072582B2/en active Active